Newsroom

Download PDF CAMBRIDGE, Mass., Feb 03, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name “ficlatuzumab” (pronounced fye” kla tue’ zue mab) for

Download PDF CAMBRIDGE, Mass., Feb 01, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell

Download PDF CAMBRIDGE, Mass., Jan 21, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported positive data from its Phase 1b clinical trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in combination with FOLFOX6, a standard chemotherapy regimen,

Download PDF CAMBRIDGE, Mass., Jan 04, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 10:00 a.m. (PST) at the Westin St. Francis Hotel in San Francisco. Mr.

Download PDF Data Underscore Potential for Tivozanib to be Safely Combined with Other Anti-Cancer Agents CAMBRIDGE, Mass. & SAN ANTONIO, Dec 10, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preliminary results from an ongoing Phase 1b clinical trial evaluating the

Download PDF CAMBRIDGE, Mass., Dec 02, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company’s lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2,

Download PDF Option Triggers $25 Million in Milestone Payments to AVEO MELVILLE, N.Y. & TOKYO & CAMBRIDGE, MASS., Dec 01, 2010 (BUSINESS WIRE) — OSI Pharmaceuticals, Inc., (“OSI”), which is a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., and AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced

Download PDF CAMBRIDGE, Mass., Nov 22, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company’s management will present a company overview at several upcoming investment conferences. David Johnston, chief financial officer, is scheduled to present at the following event: